Vaxon Biotech.

Vaxon Biotech, founded in early 2004 and based in Evry Genopole - France, is a product-driven biopharmaceutical company focusing on the discovery and development of innovative vaccines for the treatment of malignancies, including prostate, lung, breast and colon cancer.
The company is based on an original discovery made by Dr. Kostas Kosmatopoulos and his team: optimized cryptic peptides.

Vaxon Biotech's vaccines are intended to treat existing cancers (therapeutic vaccines) by stimulating the immune system to recognize and attack human cancer cells without harming normal cells. These vaccines target antigens, overexpressed in tumor cells but present in very low quantities in normal cells.

The first two products under development, Vx-001 and Vx-006, are novel treatments for solid tumors :

- Vx-001 achieved phase I clinical trial Q3-2004 and showed good tolerance and immune response ; Vx-001 should enter controlled phase II Q3 2006, in non small cell lung cancer, and in phase IIb Q4 2006, in hepatocellular cancer.

- Vx-006 should enter phase I/II clinical development early 2007, starting with prostate cancer.

Vaxon Biotech R&D expertise provides collaborative opportunities ranging from licensing options of proprietary optimized cryptic peptides to joint clinical development of therapeutic vaccine products.

Contact Details: 2 rue Gaston Crémieux Evry Genopole cedex 91057 France Tel: 33(0) 1 60 78 92 10 Fax: 33(0) 1 60 78 92 19 Email: info@vaxon-biotech.com WWW: www.vaxon-biotech.com/

Recent Publications by Vaxon Biotech.:
CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope. The use of synthetic peptides derived from tumor-associated Ags is...	2nd August, 2006	Vaxon Biotech, Genopole bat G2, 2 rue Gaston Cremieux, 91057 Evry, France.	Vaccine. 2006 Mar 10;24(11):1880-8. Epub 2005 Oct 28. DOI Direct Link
Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity. Polyspecific tumor vaccination should offer broad control of tumor cells...	29th June, 2006	Vaxon Biotech, Genopole bat G2, 2 rue Gaston Cremieux, 91057 Evry, France.	Vaccine. 2006 Mar 15;24(12):2102-9. Epub 2005 Nov 28. DOI Direct Link

BioNews Results for Vaxon Biotech.:
More Biotech Bankruptcies Might Not Be All Bad	BioWorld:  Oct 13 2008 12:40AM Matching: biotech
Pharma Giants Prowl For Biotech Startups	Hartford Business Journal:  Oct 12 2008 8:27AM Matching: biotech
BMS Seeks to Become Next-Generation Pharma	Bio-IT World:  Oct 12 2008 5:00PM Matching: biotech
www.companiesandmarkets.com: Companies and Markets announces the addition of Successful Pharmabiotech Alliance	Pharmacy Choice:  Oct 11 2008 3:42PM Matching: biotech
New York Analyst: Eli Lilly's ImClone Acquisition Carries New 'Promise, Risks'	Midwest Business:  Oct 11 2008 9:42AM Matching: biotech
Promote your company here: BioNewsCast - Press Release Distribution	→View more Vaxon Biotech. news.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 218 times since April 2007, the link to the organisation's website has been followed 41 times

Recent Search Terms used to find this page: Vaxon biotech cancer dendritic | Vaxon biotech cancer dendritic | Vaxon Biotech | vaxon | t | vaxon | Vaxon biotech | VAXON BIOTECH FRANCE VAT | VAXON BIOTECH VAT | .

Search for more companies in Evry Genopole

Search for more companies in cedex

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Vaxon Biotech.